Influenza virus-related critical illness: Pathophysiology and epidemiology

Critical Care

Volumn 23, Issue 1, 2019, Pages

  Kalil, Andre C ^a   Thomas, Paul G ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

ARDS; Complications; Epidemiology; Influenza; Pneumonia; Sepsis

Indexed keywords

ADULT RESPIRATORY DISTRESS SYNDROME; AIRWAY OBSTRUCTION; CAUCASIAN; CELL KILLING; CHRONIC LUNG DISEASE; CLINICAL OUTCOME; CRITICAL ILLNESS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; ENCEPHALITIS; EXTRACELLULAR MATRIX; GAS EXCHANGE; GROUPS BY AGE; HEART DISEASE; HOSPITAL ADMISSION; HUMAN; IMMUNOCOMPROMISED PATIENT; INDEPENDENT VARIABLE; INFLUENZA; INFLUENZA A VIRUS (H3N2); INFLUENZA B; INFLUENZA VACCINATION; INTENSIVE CARE UNIT; LABORATORY DIAGNOSIS; LOBAR PNEUMONIA; LUNG EPITHELIUM; LUNG FUNCTION; MIXED INFECTION; MYOCARDITIS; NONHUMAN; NURSING HOME PATIENT; OBESITY; PATHOPHYSIOLOGY; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; SEASONAL VARIATION; SEPSIS; SEX; SMOKING; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS AUREUS INFECTION; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; VIRUS TRANSMISSION; ADULT; COMPLICATION; FEMALE; MIDDLE AGED; MORTALITY; ORTHOMYXOVIRIDAE; PATHOGENICITY; PROTECTION; SEX FACTOR;

INFLUENZA VACCINE;

ADULT; CRITICAL ILLNESS; FEMALE; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MIDDLE AGED; OBESITY; ORTHOMYXOVIRIDAE; PROTECTIVE FACTORS; RESPIRATORY DISTRESS SYNDROME, ADULT; SEPSIS; SEX FACTORS;

EID: 85069763887     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/s13054-019-2539-x     Document Type: Review

References (87)

1. Webster RG, Braciale TJ, Monto AS, Lamb RA. Textbook of influenza. 2nd edition. ed. Chichester, West Sussex, UK; Hoboken, NJ: Wiley-Blackwell; 2013. xvii, 502 pages p.
2. Lakdawala SS, Jayaraman A, Halpin RA, Lamirande EW, Shih AR, Stockwell TB, et al. The soft palate is an important site of adaptation for transmissible influenza viruses. Nature. 2015;526(7571):122-5.
3. Nicholls JM, Bourne AJ, Chen H, Guan Y, Peiris JS. Sialic acid receptor detection in the human respiratory tract: evidence for widespread distribution of potential binding sites for human and avian influenza viruses. Respir Res. 2007;8:73.
4. Zangrillo A, Biondi-Zoccai G, Landoni G, Frati G, Patroniti N, Pesenti A, et al. Extracorporeal membrane oxygenation (ECMO) in patients with H1N1 influenza infection: a systematic review and meta-analysis including 8 studies and 266 patients receiving ECMO. Crit Care. 2013;17(1):R30.
5. Kadoglou NPE, Bracke F, Simmers T, Tsiodras S, Parissis J. Influenza infection and heart failure-vaccination may change heart failure prognosis? Heart Fail Rev. 2017;22(3):329-36.
6. Kwong JC, Schwartz KL, Campitelli MA. Acute myocardial infarction after laboratory-confirmed influenza infection. N Engl J Med. 2018;378(26):2540-1.
7. Sanders CJ, Vogel P, McClaren JL, Bajracharya R, Doherty PC, Thomas PG. Compromised respiratory function in lethal influenza infection is characterized by the depletion of type I alveolar epithelial cells beyond threshold levels. Am J Physiol Lung Cell Mol Physiol. 2013;304(7):L481-8.
8. Cardani A, Boulton A, Kim TS, Braciale TJ. Alveolar macrophages prevent lethal influenza pneumonia by inhibiting infection of type-1 alveolar epithelial cells. PLoS Pathog. 2017;13(1):e1006140.
9. Teijaro JR, Walsh KB, Cahalan S, Fremgen DM, Roberts E, Scott F, et al. Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection. Cell. 2011;146(6):980-91.
10. Boyd DF, Thomas PG. Towards integrating extracellular matrix and immunological pathways. Cytokine. 2017;98:79-86.
11. Short KR, Kroeze E, Fouchier RAM, Kuiken T. Pathogenesis of influenza-induced acute respiratory distress syndrome. Lancet Infect Dis. 2014;14(1):57-69.
12. Quantius J, Schmoldt C, Vazquez-Armendariz AI, Becker C, El Agha E, Wilhelm J, et al. Influenza virus infects epithelial stem/progenitor cells of the distal lung: impact on Fgfr2b-driven epithelial repair. PLoS Pathog. 2016;12(6):e1005544.
13. Heneghan CJ, Onakpoya I, Jones MA, Doshi P, Del Mar CB, Hama R, et al. Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data. Health Technol Assess. 2016;20(42):1-242.
14. Talmi-Frank D, Altboum Z, Solomonov I, Udi Y, Jaitin DA, Klepfish M, et al. Extracellular matrix proteolysis by MT1-MMP contributes to Influenza-related tissue damage and mortality. Cell Host Microbe. 2016;20(4):458-70.
15. Rojas-Quintero J, Wang X, Tipper J, Burkett PR, Zuniga J, Ashtekar AR, et al. Matrix metalloproteinase-9 deficiency protects mice from severe influenza A viral infection. JCI Insight. 2018;3(24). https://doi.org/10.1172/jci.insight.99022.
16. Allen IC, Scull MA, Moore CB, Holl EK, McElvania-TeKippe E, Taxman DJ, et al. The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA. Immunity. 2009;30(4):556-65.
17. Thomas PG, Dash P, Aldridge JR Jr, Ellebedy AH, Reynolds C, Funk AJ, et al. The intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via the regulation of caspase-1. Immunity. 2009;30(4):566-75.
18. Ren R, Wu S, Cai J, Yang Y, Ren X, Feng Y, et al. The H7N9 influenza A virus infection results in lethal inflammation in the mammalian host via the NLRP3-caspase-1 inflammasome. Sci Rep. 2017;7(1):7625.
19. Tate MD, Ong JD, Dowling JK, McAuley JL, Robertson AB, Latz E, et al. Reassessing the role of the NLRP3 inflammasome during pathogenic influenza A virus infection via temporal inhibition. Sci Rep. 2016;6:27912.
20. Tavares LP, Garcia CC, Machado MG, Queiroz-Junior CM, Barthelemy A, Trottein F, et al. CXCR1/2 antagonism is protective during Influenza and post-influenza pneumococcal infection. Front Immunol. 2017;8:1799.
21. Narasaraju T, Yang E, Samy RP, Ng HH, Poh WP, Liew AA, et al. Excessive neutrophils and neutrophil extracellular traps contribute to acute lung injury of influenza pneumonitis. Am J Pathol. 2011;179(1):199-210.
22. Zhu L, Liu L, Zhang Y, Pu L, Liu J, Li X, et al. High level of neutrophil extracellular traps correlates with poor prognosis of severe Influenza a infection. J Infect Dis. 2018;217(3):428-37.
23. Jia X, Liu B, Bao L, Lv Q, Li F, Li H, et al. Delayed oseltamivir plus sirolimus treatment attenuates H1N1 virus-induced severe lung injury correlated with repressed NLRP3 inflammasome activation and inflammatory cell infiltration. PLoS Pathog. 2018;14(11):e1007428.
24. Wang CH, Chung FT, Lin SM, Huang SY, Chou CL, Lee KY, et al. Adjuvant treatment with a mammalian target of rapamycin inhibitor, sirolimus, and steroids improves outcomes in patients with severe H1N1 pneumonia and acute respiratory failure. Crit Care Med. 2014;42(2):313-21.
25. Sun X, Song L, Feng S, Li L, Yu H, Wang Q, et al. Fatty acid metabolism is associated with disease severity after H7N9 infection. EBioMedicine. 2018;33:218-29.
26. Wang A, Huen SC, Luan HH, Yu S, Zhang C, Gallezot JD, et al. Opposing effects of fasting metabolism on tissue tolerance in bacterial and viral inflammation. Cell. 2016;166(6):1512-25 e12.
27. Smallwood HS, Duan S, Morfouace M, Rezinciuc S, Shulkin BL, Shelat A, et al. Targeting metabolic reprogramming by influenza infection for therapeutic intervention. Cell Rep. 2017;19(8):1640-53.
28. Thai M, Thaker SK, Feng J, Du Y, Hu H, Ting Wu T, et al. MYC-induced reprogramming of glutamine catabolism supports optimal virus replication. Nat Commun. 2015;6:8873.
29. Maier HE, Lopez R, Sanchez N, Ng S, Gresh L, Ojeda S, et al. Obesity increases the duration of influenza a virus shedding in adults. J Infect Dis. 2018;218(9):1378-82.
30. O'Brien KB, Vogel P, Duan S, Govorkova EA, Webby RJ, McCullers JA, et al. Impaired wound healing predisposes obese mice to severe influenza virus infection. J Infect Dis. 2012;205(2):252-61.
31. Paich HA, Sheridan PA, Handy J, Karlsson EA, Schultz-Cherry S, Hudgens MG, et al. Overweight and obese adult humans have a defective cellular immune response to pandemic H1N1 influenza A virus. Obesity (Silver Spring). 2013;21(11):2377-86.
32. Casalino E, Antoniol S, Fidouh N, Choquet C, Lucet JC, Duval X, et al. Influenza virus infections among patients attending emergency department according to main reason to presenting to ED: a 3-year prospective observational study during seasonal epidemic periods. PLoS One. 2017;12(8):e0182191.
33. Maruyama T, Fujisawa T, Suga S, Nakamura H, Nagao M, Taniguchi K, et al. Outcomes and prognostic features of patients with Influenza requiring hospitalization and receiving early antiviral therapy: a prospective multicenter cohort study. Chest. 2016;149(2):526-34.
34. Garg S, Jain S, Dawood FS, Jhung M, Perez A, D'Mello T, et al. Pneumonia among adults hospitalized with laboratory-confirmed seasonal influenza virus infection-United States, 2005-2008. BMC Infect Dis. 2015;15:369.
35. Uyeki TM, Bernstein HH, Bradley JS, Englund JA, File TM Jr, Fry AM, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza. Clin Infect Dis. 2019;68(6):e1-e47. https://doi.org/10.1093/cid/ciy866.
36. Louie JK, Acosta M, Winter K, Jean C, Gavali S, Schechter R, et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA. 2009;302(17):1896-902.
37. Writing Committee of the WHOCoCAoPI, Bautista E, Chotpitayasunondh T, Gao Z, Harper SA, Shaw M, et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med. 2010;362(18):1708-19.
38. Burrell A, Huckson S, Pilcher DV, Anzics. ICU admissions for Sepsis or pneumonia in Australia and New Zealand in 2017. N Engl J Med. 2018;378(22):2138-9.
39. Ike JD, Kempker JA, Kramer MR, Martin GS. The association between acute respiratory distress syndrome hospital case volume and mortality in a U.S. cohort, 2002-2011. Crit Care Med. 2018;46(5):764-73.
40. Schouten LR, Veltkamp F, Bos AP, van Woensel JB, Serpa Neto A, Schultz MJ, et al. Incidence and mortality of acute respiratory distress syndrome in children: a systematic review and meta-analysis. Crit Care Med. 2016;44(4):819-29.
41. Bonmarin Isabelle BE, Jean B, Christian B-B, Bruno M, Loup CJ, Bruno H, Yann LS, Daniel L-B. Intensive care unit surveillance of influenza infection in France: the 2009/10 pandemic and the three subsequent seasons. Euro Surveill. 2015;20(46).
42. Li H, Weng H, Lan C, Zhang H, Wang X, Pan J, et al. Comparison of patients with avian influenza A (H7N9) and influenza a (H1N1) complicated by acute respiratory distress syndrome. Medicine (Baltimore). 2018;97(12):e0194.
43. Groeneveld GH, van Paassen J, van Dissel JT, Arbous MS. Influenza season and ARDS after cardiac surgery. N Engl J Med. 2018;378(8):772-3.
44. Zhou F, Li H, Gu L, Liu M, Xue CX, Cao B, et al. Risk factors for nosocomial infection among hospitalised severe influenza A(H1N1)pdm09 patients. Respir Med. 2018;134:86-91.
45. Dugas AF, Valsamakis A, Atreya MR, Thind K, Alarcon Manchego P, Faisal A, et al. Clinical diagnosis of influenza in the ED. Am J Emerg Med. 2015;33(6):770-5.
46. van Asten L, Luna Pinzon A, de Lange DW, de Jonge E, Dijkstra F, Marbus S, et al. Estimating severity of influenza epidemics from severe acute respiratory infections (SARI) in intensive care units. Crit Care. 2018;22(1):351.
47. Steinberg BE, Goldenberg NM, Lee WL. Do viral infections mimic bacterial sepsis? The role of microvascular permeability: a review of mechanisms and methods. Antivir Res. 2012;93(1):2-15.
48. Florescu DF, Kalil AC. The complex link between influenza and severe sepsis. Virulence. 2014;5(1):137-42.
49. Imai Y, Kuba K, Neely GG, Yaghubian-Malhami R, Perkmann T, van Loo G, et al. Identification of oxidative stress and toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell. 2008;133(2):235-49.
50. Nhu QM, Shirey K, Teijaro JR, Farber DL, Netzel-Arnett S, Antalis TM, et al. Novel signaling interactions between proteinase-activated receptor 2 and Toll-like receptors in vitro and in vivo. Mucosal Immunol. 2010;3(1):29-39.
51. Shirey KA, Lai W, Scott AJ, Lipsky M, Mistry P, Pletneva LM, et al. The TLR4 antagonist Eritoran protects mice from lethal influenza infection. Nature. 2013;497(7450):498-502.
52. Friesenhagen J, Boergeling Y, Hrincius E, Ludwig S, Roth J, Viemann D. Highly pathogenic avian influenza viruses inhibit effective immune responses of human blood-derived macrophages. J Leukoc Biol. 2012;92(1):11-20.
53. Cheung CY, Poon LL, Lau AS, Luk W, Lau YL, Shortridge KF, et al. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet. 2002;360(9348):1831-7.
54. Sakabe S, Iwatsuki-Horimoto K, Takano R, Nidom CA, Le M, Nagamura-Inoue T, et al. Cytokine production by primary human macrophages infected with highly pathogenic H5N1 or pandemic H1N1 2009 influenza viruses. J Gen Virol. 2011;92(Pt 6):1428-34.
55. Wang S, Le TQ, Kurihara N, Chida J, Cisse Y, Yano M, et al. Influenza virus-cytokine-protease cycle in the pathogenesis of vascular hyperpermeability in severe influenza. J Infect Dis. 2010;202(7):991-1001.
56. Armstrong SM, Mubareka S, Lee WL. The lung microvascular endothelium as a therapeutic target in severe influenza. Antivir Res. 2013;99(2):113-8.
57. Jain S, Benoit SR, Skarbinski J, Bramley AM, Finelli L, Pandemic Influenza AVHIT. Influenza-associated pneumonia among hospitalized patients with 2009 pandemic influenza A (H1N1) virus - United States, 2009. Clin Infect Dis. 2012;54(9):1221-9.
58. Kumar A, Zarychanski R, Pinto R, Cook DJ, Marshall J, Lacroix J, et al. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA. 2009;302(17):1872-9.
59. Dominguez-Cherit G, Lapinsky SE, Macias AE, Pinto R, Espinosa-Perez L, de la Torre A, et al. Critically ill patients with 2009 influenza A(H1N1) in Mexico. JAMA. 2009;302(17):1880-7.
60. Farias JA, Fernandez A, Monteverde E, Vidal N, Arias P, Montes MJ, et al. Critically ill infants and children with influenza A (H1N1) in pediatric intensive care units in Argentina. Intensive Care Med. 2010;36(6):1015-22.
61. Southeast Asia Infectious Disease Clinical Research N. Causes and outcomes of sepsis in Southeast Asia: a multinational multicentre cross-sectional study. Lancet Glob Health. 2017;5(2):e157-e67.
62. Aliberti S, Kaye KS. The changing microbiologic epidemiology of community-acquired pneumonia. Postgrad Med. 2013;125(6):31-42.
63. Self WH, Balk RA, Grijalva CG, Williams DJ, Zhu Y, Anderson EJ, et al. Procalcitonin as a marker of etiology in adults hospitalized with community-acquired pneumonia. Clin Infect Dis. 2017;65(2):183-90.
64. Cawcutt K, Kalil AC. Pneumonia with bacterial and viral coinfection. Curr Opin Crit Care. 2017;23(5):385-90.
65. Voiriot G, Visseaux B, Cohen J, Nguyen LB, Neuville M, Morbieu C, et al. Viral-bacterial coinfection affects the presentation and alters the prognosis of severe community-acquired pneumonia. Crit Care. 2016;20(1):375.
66. Self WH, Williams DJ, Zhu Y, Ampofo K, Pavia AT, Chappell JD, et al. Respiratory viral detection in children and adults: comparing asymptomatic controls and patients with community-acquired pneumonia. J Infect Dis. 2016;213(4):584-91.
67. Diaz MH, Cross KE, Benitez AJ, Hicks LA, Kutty P, Bramley AM, et al. Identification of bacterial and viral codetections with mycoplasma pneumoniae using the TaqMan array card in patients hospitalized with community-acquired pneumonia. Open Forum Infect Dis. 2016;3(2):ofw071.
68. Loubet P, Voiriot G, Houhou-Fidouh N, Neuville M, Bouadma L, Lescure FX, et al. Impact of respiratory viruses in hospital-acquired pneumonia in the intensive care unit: a single-center retrospective study. J Clin Virol. 2017;91:52-7.
69. Shorr AF, Zilberberg MD, Micek ST, Kollef MH. Viruses are prevalent in non-ventilated hospital-acquired pneumonia. Respir Med. 2017;122:76-80.
70. Hong HL, Hong SB, Ko GB, Huh JW, Sung H, Do KH, et al. Viral infection is not uncommon in adult patients with severe hospital-acquired pneumonia. PLoS One. 2014;9(4):e95865.
71. Aykac K, Karadag-Oncel E, Tanir Basaranoglu S, Alp A, Cengiz AB, Ceyhan M, et al. Respiratory viral infections in infants with possible sepsis. J Med Virol. 2019;91(2):171-8.
72. Ljungstrom LR, Jacobsson G, Claesson BEB, Andersson R, Enroth H. Respiratory viral infections are underdiagnosed in patients with suspected sepsis. Eur J Clin Microbiol Infect Dis. 2017;36(10):1767-76.
73. Cawcutt KA, Kalil AC. Viral and bacterial co-infection in pneumonia: do we know enough to improve clinical care? Crit Care. 2017;21(1):19.
74. Martin-Loeches I, J Schultz M, Vincent JL, Alvarez-Lerma F, Bos LD, Sole-Violan J, et al. Increased incidence of co-infection in critically ill patients with influenza. Intensive Care Med. 2017;43(1):48-58.
75. Randolph AG, Vaughn F, Sullivan R, Rubinson L, Thompson BT, Yoon G, et al. Critically ill children during the 2009-2010 influenza pandemic in the United States. Pediatrics. 2011;128(6):e1450-8.
76. Rice TW, Rubinson L, Uyeki TM, Vaughn FL, John BB, Miller RR 3rd, et al. Critical illness from 2009 pandemic influenza A virus and bacterial coinfection in the United States. Crit Care Med. 2012;40(5):1487-98.
77. Rozencwajg S, Brechot N, Schmidt M, Hekimian G, Lebreton G, Besset S, et al. Co-infection with influenza-associated acute respiratory distress syndrome requiring extracorporeal membrane oxygenation. Int J Antimicrob Agents. 2018;51(3):427-33.
78. Randolph AG, Xu R, Novak T, Newhams MM, Bubeck Wardenburg J, Weiss SL, et al. Vancomycin monotherapy may be insufficient to treat methicillin-resistant Staphylococcus aureus coinfection in children with influenza-related critical illness. Clin Infect Dis. 2019;68(3):365-72.
79. Ghoneim HE, Thomas PG, McCullers JA. Depletion of alveolar macrophages during influenza infection facilitates bacterial superinfections. J Immunol. 2013;191(3):1250-9.
80. Goulding J, Godlee A, Vekaria S, Hilty M, Snelgrove R, Hussell T. Lowering the threshold of lung innate immune cell activation alters susceptibility to secondary bacterial superinfection. J Infect Dis. 2011;204(7):1086-94.
81. Jamieson AM, Yu S, Annicelli CH, Medzhitov R. Influenza virus-induced glucocorticoids compromise innate host defense against a secondary bacterial infection. Cell Host Microbe. 2010;7(2):103-14.
82. Dell KM, Schulman SL. Rhabdomyolysis and acute renal failure in a child with influenza a infection. Pediatr Nephrol. 1997;11(3):363-5.
83. Mamas MA, Fraser D, Neyses L. Cardiovascular manifestations associated with influenza virus infection. Int J Cardiol. 2008;130(3):304-9.
84. Paddock CD, Liu L, Denison AM, Bartlett JH, Holman RC, Deleon-Carnes M, et al. Myocardial injury and bacterial pneumonia contribute to the pathogenesis of fatal influenza B virus infection. J Infect Dis. 2012;205(6):895-905.
85. Goenka A, Michael BD, Ledger E, Hart IJ, Absoud M, Chow G, et al. Neurological manifestations of influenza infection in children and adults: results of a National British Surveillance Study. Clin Infect Dis. 2014;58(6):775-84.
86. Okuno H, Yahata Y, Tanaka-Taya K, Arai S, Satoh H, Morino S, et al. Characteristics and outcomes of Influenza-associated encephalopathy cases among children and adults in Japan, 2010-2015. Clin Infect Dis. 2018;66(12):1831-7.
87. Sellers SA, Hagan RS, Hayden FG, Fischer WA 2nd. The hidden burden of influenza: a review of the extra-pulmonary complications of influenza infection. Influenza Other Respir Viruses. 2017;11(5):372-93.